Genovese D, Brinch D, Muscarella S, Saladino M, Carrozza L, Cunsolo C
Healthcare (Basel). 2025; 13(5).
PMID: 40077070
PMC: 11898406.
DOI: 10.3390/healthcare13050508.
Ali S, Giovanetti M, Johnston C, Urdaneta-Paez V, Azarian T, Cella E
Pathogens. 2025; 13(12.
PMID: 39770354
PMC: 11679505.
DOI: 10.3390/pathogens13121095.
Wang H, Peng Q, Dai X, Ying Z, Wu X, Liu X
MedComm (2020). 2025; 6(1):e779.
PMID: 39760111
PMC: 11695206.
DOI: 10.1002/mco2.779.
Bayarri-Olmos R, Sutta A, Rosbjerg A, Mortensen M, Helgstrand C, Nielsen P
Front Immunol. 2024; 15:1412873.
PMID: 39720734
PMC: 11666439.
DOI: 10.3389/fimmu.2024.1412873.
Djorwe S, Malki A, Nzoyikorera N, Nyandwi J, Zebsoubo S, Bellamine K
Access Microbiol. 2024; 6(10).
PMID: 39376591
PMC: 11457919.
DOI: 10.1099/acmi.0.000853.v4.
Evaluation of Neutralizing Capacity of Tixagevimab plus Cilgavimab (AZD7442) against Different SARS-CoV-2 Variants: A Case Report Study with Comparison to a Vaccinated Population.
Gillot C, Bayart J, Maloteau V, Dogne J, Douxfils J, Favresse J
Case Rep Infect Dis. 2024; 2024:9163490.
PMID: 39246664
PMC: 11380708.
DOI: 10.1155/2024/9163490.
Insights from an observational translational research program during the COVID-19 pandemic: Four years of experience.
Rowe M, Collier A, Barouch D
Vaccine. 2024; 42(24):126306.
PMID: 39241351
PMC: 11401756.
DOI: 10.1016/j.vaccine.2024.126306.
Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses.
Paciello I, Pierleoni G, Pantano E, Antonelli G, Pileri P, Maccari G
Cell Rep. 2024; 43(9):114645.
PMID: 39207904
PMC: 11422482.
DOI: 10.1016/j.celrep.2024.114645.
Molecular epidemiology and population immunity of SARS-CoV-2 in Guangdong (2022-2023) following a pivotal shift in the pandemic.
Li Z, Hu P, Qu L, Yang M, Qiu M, Xie C
Nat Commun. 2024; 15(1):7033.
PMID: 39147778
PMC: 11327343.
DOI: 10.1038/s41467-024-51141-y.
Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.
Benlarbi M, Ding S, Belanger E, Tauzin A, Poujol R, Medjahed H
mBio. 2024; 15(8):e0090724.
PMID: 38953636
PMC: 11323525.
DOI: 10.1128/mbio.00907-24.
Durability of immune responses to SARS-CoV-2 infection and vaccination.
Suthar M
Semin Immunol. 2024; 73:101884.
PMID: 38861769
PMC: 11490408.
DOI: 10.1016/j.smim.2024.101884.
Non-cross-reactive epitopes dominate the humoral immune response to COVID-19 vaccination - kinetics of plasma antibodies, plasmablasts and memory B cells.
Wietschel K, Fechtner K, Antileo E, Abdurrahman G, Drechsler C, Makuvise M
Front Immunol. 2024; 15:1382911.
PMID: 38807606
PMC: 11130424.
DOI: 10.3389/fimmu.2024.1382911.
The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses.
Martinez D, Moreira F, Catanzaro N, Diefenbacher M, Zweigart M, Gully K
Sci Transl Med. 2024; 16(748):eadj4504.
PMID: 38776389
PMC: 11333937.
DOI: 10.1126/scitranslmed.adj4504.
A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
Iwata S, Pollard A, Tada Y, Omoto S, Shibata R, Igarashi K
Sci Rep. 2024; 14(1):9830.
PMID: 38684712
PMC: 11059267.
DOI: 10.1038/s41598-024-57308-3.
Evaluation of T Cell Response to SARS-CoV-2 in Kidney Transplant Recipients Receiving Monoclonal Antibody Prophylaxis and the Utility of a Bivalent mRNA Vaccine Booster Dose.
Bertrand D, Laurent C, Lemoine M, Lebourg L, Hanoy M, Le Roy F
Microorganisms. 2024; 12(4).
PMID: 38674666
PMC: 11052329.
DOI: 10.3390/microorganisms12040722.
An ancestral SARS-CoV-2 vaccine induces anti-Omicron variants antibodies by hypermutation.
Park S, Choi J, Lee Y, Noh J, Kim N, Lee J
Nat Commun. 2024; 15(1):3368.
PMID: 38643233
PMC: 11032360.
DOI: 10.1038/s41467-024-47743-1.
Predicting Vaccine Effectiveness for Hospitalization and Symptomatic Disease for Novel SARS-CoV-2 Variants Using Neutralizing Antibody Titers.
Gardner B, Kilpatrick A
Viruses. 2024; 16(3).
PMID: 38543844
PMC: 10975673.
DOI: 10.3390/v16030479.
Anti SARS-CoV-2 Monoclonal Antibodies in Pre-Exposure or Post-Exposure in No- or Weak Responder to Vaccine Kidney Transplant Recipients: Is One Strategy Better than Another?.
Romero A, Laurent C, Lebourg L, Lemee V, Hanoy M, Le Roy F
Viruses. 2024; 16(3).
PMID: 38543747
PMC: 10975193.
DOI: 10.3390/v16030381.
Long-term analysis of humoral responses and spike-specific T cell memory to Omicron variants after different COVID-19 vaccine regimens.
Ho C, Yen L, Huang H, Lu C, Hung Y, Liao C
Front Immunol. 2024; 15:1340645.
PMID: 38533494
PMC: 10963495.
DOI: 10.3389/fimmu.2024.1340645.
COVID-19 vaccines: Immune correlates and clinical outcomes.
Mahrokhian S, Tostanoski L, Vidal S, Barouch D
Hum Vaccin Immunother. 2024; 20(1):2324549.
PMID: 38517241
PMC: 10962618.
DOI: 10.1080/21645515.2024.2324549.
